Chiesi buys into Arbor gene editing drug for rare kidney disease

Chiesi buys into Arbor gene editing drug for rare kidney disease

The Italian drugmaker will pay as much as $115 million in upfront and near-term payments in a deal that gives it rights to a treatment in early-stage testing for primary hyperoxaluria type 1.

Arbor partners with Chiesi Group in gene editing deal with potential $2B future payments

Chiesi Group is getting into CRISPR. The Italian drugmaker on Monday announced a deal with Arbor Biotechnologies to license and develop its gene editing therapy for a rare condition called primary hyperoxaluria type 1 ...